# Triple Combination Therapy in High Risk Crohn's Disease (CD)

> **NCT02764762** · PHASE4 · COMPLETED · sponsor: **Takeda** · enrollment: 55 (actual)

## Conditions studied

- Crohn Disease

## Interventions

- **DRUG:** Vedolizumab
- **DRUG:** Adalimumab
- **DRUG:** Methotrexate

## Key facts

- **NCT ID:** NCT02764762
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-18
- **Primary completion:** 2020-09-22
- **Final completion:** 2022-07-05
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2023-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02764762

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02764762, "Triple Combination Therapy in High Risk Crohn's Disease (CD)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02764762. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*